{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:31:00Z","timestamp":1787142660779,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"17","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To examine interventions, recommendations, and direct cost avoidance from integrated outpatient specialty neurology pharmacists in the non\u2013multiple sclerosis (MS) setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center, retrospective cohort study was performed, including patients prescribed specialty medications from non-MS neurology clinics with at least one pharmacist intervention from January to March 2023. Outcomes included pharmacist intervention types, intervention recommendations to patients and providers, and direct cost avoidance from interventions. Cost avoidance was calculated by summing the total costs (average wholesale price minus 20%) of one fill of medications that were discontinued or had a dose change as a result of an intervention or refill deferral. Patients who used excess supply on hand from a previous fill were accounted for during the calculation. The cost per unit of each medication\/dosage was multiplied by the quantity of the last medication fill to calculate the cost avoided.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 741 patients with a median age of 60 (interquartile range, 22-72) years; 83% were White; 55% were male; and 69% used the integrated health-system specialty pharmacy (IHSSP) for medication fulfillment. Pharmacists performed 2,244 interventions, generating 392 recommendations, with a 98% acceptance rate. The most common recommendation outcomes were medication changes (34%, n = 129) and financial assistance referrals (17%, n = 64). During the 3-month study period, discontinuations and dose changes resulted in $172,757 in direct cost avoidance for IHSSP patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IHSSP neurology pharmacists in the non-MS setting frequently perform interventions that result in therapy changes and direct cost avoidance. IHSSP pharmacist interventions benefit patients, providers, the healthcare system, and insurers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag088","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:41:43Z","timestamp":1774010503000},"page":"e691-e698","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and economic benefits of pharmacist interventions in a non\u2013multiple sclerosis neurology clinic"],"prefix":"10.1093","volume":"83","author":[{"given":"Kayla","family":"Johnson","sequence":"first","affiliation":[{"name":"Vanderbilt Specialty Pharmacy, Vanderbilt Health System , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Kaveh","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center College of Pharmacy , Knoxville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Livezey","sequence":"additional","affiliation":[{"name":"Vanderbilt Specialty Pharmacy, Vanderbilt Health System , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-7090","authenticated-orcid":false,"given":"Leena","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Autumn D","family":"Zuckerman","sequence":"additional","affiliation":[{"name":"Vanderbilt Specialty Pharmacy, Vanderbilt Health System , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Cruchelow","sequence":"additional","affiliation":[{"name":"Vanderbilt Specialty Pharmacy, Vanderbilt Health System , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"21","key":"2026081907561775500_zxag088-B1","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/ajhp\/zxac212","article-title":"Health-system specialty pharmacy role and outcomes: a review of current literature","volume":"79","author":"Zuckerman","year":"2022","journal-title":"Am J Health-Syst Pharm"},{"issue":"4","key":"2026081907561775500_zxag088-B2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/pharmacy7040163","article-title":"An integrated health-system specialty pharmacy model for coordinating transitions of care: specialty medication challenges and specialty pharmacist opportunities","volume":"7","author":"Zuckerman","year":"2019","journal-title":"Pharmacy (Basel)"},{"key":"2026081907561775500_zxag088-B3","doi-asserted-by":"publisher","first-page":"103860","DOI":"10.1016\/j.msard.2022.103860","article-title":"A cross-sectional analysis of persistence to disease-modifying therapies in treatment na\u00efve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy","volume":"63","author":"Kozlicki","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"2026081907561775500_zxag088-B4","doi-asserted-by":"publisher","first-page":"e3555","DOI":"10.4212\/cjhp.3555","article-title":"Describing and evaluating the clinical pharmacist\u2019s role in a Canadian multiple sclerosis clinic","volume":"77","author":"Busque","year":"2024","journal-title":"Can J Hosp Pharm"},{"issue":"suppl 2","key":"2026081907561775500_zxag088-B5","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1093\/ajhp\/zxae024","article-title":"Health-system specialty pharmacist intervention types, acceptance, and associated actions for patients with multiple sclerosis","volume":"81","author":"El-Khouri","year":"2024","journal-title":"Am J Health-Syst Pharm"},{"issue":"4","key":"2026081907561775500_zxag088-B6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.18553\/jmcp.2024.30.4.336","article-title":"Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis","volume":"30","author":"Georgieva","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"2026081907561775500_zxag088-B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7224\/1537-2073.2022-051","article-title":"The role of clinical pharmacists in patient-centric comprehensive multiple sclerosis care","volume":"26","author":"Bainbridge","year":"2024","journal-title":"Int J MS Care"},{"issue":"12","key":"2026081907561775500_zxag088-B8","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.18553\/jmcp.2021.27.12.1664","article-title":"Evaluation of the impact of a clinical pharmacist on a specialty neurology clinic\u2019s adherence to recommended laboratory test monitoring","volume":"27","author":"Darby","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"2026081907561775500_zxag088-B9","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.japh.2022.07.006","article-title":"Specialty pharmacy integration and the role of an advanced certified pharmacy technician in prescription cannabidiol access","volume":"62","author":"Owens","year":"(2003). 2022","journal-title":"J Am Pharm Assoc"},{"issue":"18","key":"2026081907561775500_zxag088-B10","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/ajhp\/zxac155","article-title":"Prescription cannabidiol for seizure disorder management: Initial drug-drug interaction management by specialty pharmacists","volume":"79","author":"Dial","year":"2022","journal-title":"Am J Health-Syst Pharm"},{"issue":"2","key":"2026081907561775500_zxag088-B11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.japh.2024.01.010","article-title":"Benefit of clinical pharmacists in neurology clinics at an academic medical center","volume":"64","author":"Anderson","year":"2024","journal-title":"J Am Pharm Assoc"},{"issue":"8","key":"2026081907561775500_zxag088-B12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.18553\/jmcp.2017.23.8.815","article-title":"Advancing patient care through specialty pharmacy services in an academic health system","volume":"23","author":"Bagwell","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"2026081907561775500_zxag088-B13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (Redcap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026081907561775500_zxag088-B14","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2026081907561775500_zxag088-B15","author":"R Core Team"},{"issue":"6","key":"2026081907561775500_zxag088-B16","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.japh.2022.06.002","article-title":"Droxidopa management by an integrated health-system specialty pharmacy team","volume":"62","author":"Livezey","year":"2022","journal-title":"J Am Pharm Assoc"},{"issue":"5","key":"2026081907561775500_zxag088-B17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/0897190018824821","article-title":"Adherence to disease-modifying therapies at a multiple sclerosis clinic: the role of the specialty pharmacist","volume":"33","author":"Banks","year":"2020","journal-title":"J Pharm Pract"},{"issue":"7","key":"2026081907561775500_zxag088-B18","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.amjmed.2023.03.007","article-title":"Patient-tailored interventions to improve specialty medication adherence: results from a prospective randomized controlled trial","volume":"136","author":"Kibbons","year":"2023","journal-title":"Am J Med"},{"issue":"2","key":"2026081907561775500_zxag088-B19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.18553\/jmcp.2020.26.2.95","article-title":"The effect of an integrated health system specialty pharmacy on HIV antiretroviral therapy adherence, viral suppression, and CD4 count in an outpatient infectious disease clinic","volume":"26","author":"Barnes","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"14","key":"2026081907561775500_zxag088-B20","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/ajhp\/zxaa135","article-title":"Comparison of rates of adherence to oral chemotherapy medications filled through an internal health-system specialty pharmacy vs external specialty pharmacies","volume":"77","author":"McCabe","year":"2020","journal-title":"Am J Health-Syst Pharm"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag088\/67434909\/zxag088.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/17\/e691\/67434909\/zxag088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/17\/e691\/67434909\/zxag088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:56:23Z","timestamp":1787140583000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/17\/e691\/8530635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":20,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,3,20]]},"published-print":{"date-parts":[[2026,8,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag088","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,1]]},"published":{"date-parts":[[2026,3,20]]}}}